We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies.
Switching Language
Please note that your current login session is only valid on the English site (letpub.com). You will not be signed in on other language versions of the site. If you wish to place an order, please return to the English site.
New Free Tool: Verity — Pre-Submission Manuscript Check
Automatically checks your manuscript across 34 criteria including structure, metadata, disclosures, and language issues before you submit to your target journal.
Acta Pharmaceutica (AP) is an international, scientific, multidisciplinary journal, devoted to the pharmaceutical and allied sciences, which contains articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With a strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice, in the form of preliminary and short communications, original research papers and reviews. Book reviews are published also.
AP is a quarterly, single-blind peer-reviewed journal in biomedicine with fully open access and “early bird” platform. All articles are submitted to scrutinized evaluation and fair judgement. AP above all puts scientific honesty and integrity.
To reach the highest standards in publication ethics all the parties (authors, editors, reviewers) are required to behave responsibly and ethically. This implies submittance by authors on an exclusive basis, of only their own and new data; novelty and originality are prioritized. Also, secure handling of confidential data by reviewers and editors is a must.
AP is indexed in numerous world top international bibliographic bases, like Clarivate Analytics´s Web of Science® Core Collection (SCI-Expanded, JCR/Science Edition, etc.), EMBASE/Excerpta Medica, MEDLINE/PubMed, Scopus/SCImago, and others. According to SCImago JR it is a Q2 journal (pharmaceutical sciences) with a steadily increasing Clarivate JIF value reaching 2.8 in 2022.
